Presentation is loading. Please wait.

Presentation is loading. Please wait.

IMPI Trial design: Participants with TB pericarditis and risk for HIV were randomized to prednisolone (n = 706) vs. placebo (n = 694) and to M. indicus.

Published byJohnathan Higgins Modified over 6 years ago

Similar presentations

Presentation on theme: "IMPI Trial design: Participants with TB pericarditis and risk for HIV were randomized to prednisolone (n = 706) vs. placebo (n = 694) and to M. indicus."— Presentation transcript:

1 IMPI Trial design: Participants with TB pericarditis and risk for HIV were randomized to prednisolone (n = 706) vs. placebo (n = 694) and to M. indicus pranii immunotherapy over 3 months (n = 625) vs. placebo injections (n = 625). (p = 0.66) (p = 0.81) Results Glucocorticoid stratum: Death, tamponade requiring pericardiocentesis, or constrictive pericarditis: 23.8% of the prednisolone group vs. 24.5% of the placebo group (p = 0.66) Immunotherapy stratum: Death, tamponade requiring pericardiocentesis, or constrictive pericarditis: 25.0% of the immunotherapy group vs. 24.3% of the placebo group (p = 0.81) 23.8 24.5 25.0 24.3 % % Conclusions Among participants with TB pericarditis, neither prednisolone therapy nor M. indicus pranii immunotherapy was associated with a reduction in the primary outcome Glucocorticoid stratum Immunotherapy stratum Prednisolone Immunotherapy Placebo Placebo Mayosi BM, et al. N Engl J Med 2014;371:

Download ppt "IMPI Trial design: Participants with TB pericarditis and risk for HIV were randomized to prednisolone (n = 706) vs. placebo (n = 694) and to M. indicus."

Similar presentations

Cardiovascular outcome in patients with dysglycemia with daily supplementation of n-3 fatty acids 1 ORIGIN trial (Outcome Reduction with an Initial Glargine.

Cardiovascular outcome in patients with dysglycemia with daily supplementation of n-3 fatty acids 1 ORIGIN trial (Outcome Reduction with an Initial Glargine.
The Investigation of the Management of Pericarditis The IMPI Trial (‘ee-MP-ee’ means Warriors in Zulu)

The Investigation of the Management of Pericarditis The IMPI Trial (‘ee-MP-ee’ means Warriors in Zulu)
Randomized, double-blind, multicenter, controlled trial.

Randomized, double-blind, multicenter, controlled trial.
Frank B. Hu et al N Engl J Med 2004; 351: 2694- 703 Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.

Frank B. Hu et al N Engl J Med 2004; 351: Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.
Design of Phase III Microbicide Trials: Choice of Control Group August 20, 2003 Rosalie Dominik, DrPH Director of Biostatistics Institute for Family Health.

Design of Phase III Microbicide Trials: Choice of Control Group August 20, 2003 Rosalie Dominik, DrPH Director of Biostatistics Institute for Family Health.
Duality of interests B.M. Mayosi has received research grants from AstraZeneca, Cadila Pharma, Novartis, Pfizer, Roche, and Servier.

Duality of interests B.M. Mayosi has received research grants from AstraZeneca, Cadila Pharma, Novartis, Pfizer, Roche, and Servier.
Prevention of Recurrent Venous Thromboembolism N Engl J Med Apr 10 2003;348(15) :1425-1434 PREVENT (Warfarin) Trial.

Prevention of Recurrent Venous Thromboembolism N Engl J Med Apr ;348(15) : PREVENT (Warfarin) Trial.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.

LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.
The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.
Flow Diagram of Identification of Randomized Trials for Inclusion Goran Bjelakovic, et al. JAMA. 2007;297:842-857.

Flow Diagram of Identification of Randomized Trials for Inclusion Goran Bjelakovic, et al. JAMA. 2007;297:
COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker,

COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker,
Www.company.com 내과 R2 이지훈 N Engl J Med 2014;371:1121-1130.

내과 R2 이지훈 N Engl J Med 2014;371:
The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.

The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.
(p for noninferiority = 0.01)

(p for noninferiority = 0.01)
IRIS Trial design: Patients without diabetes with a history of stroke or TIA within 6 months, with objective evidence of insulin resistance (HOMA-IR value.

IRIS Trial design: Patients without diabetes with a history of stroke or TIA within 6 months, with objective evidence of insulin resistance (HOMA-IR value.
LEADER trial: Primary Outcome

LEADER trial: Primary Outcome
NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.

NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.
CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.
SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

Similar presentations

Ads by Google